NCT04975490|Unknown
Characterization and Pathogenesis of ACLF
ACLF-I
Beobachtungsstudie für Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens
Loading search results
ACLF-I
Beobachtungsstudie für Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens
Sponsor study identifier
observational
1,000
1 country
1
Study Start
December 1, 2020
Actual (reported)Primary Completion
September 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 1, 2020
Actual (reported)July 14, 2021
Actual (reported)July 23, 2021
Actual (reported)September 30, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Mortality
number of patients
90 days
Patient with liver cirrhosis and complications
Translational Hepatology
Frankfurt am Main, Hesse, 60590, Germany
Thiyagarajah K, Sonnenberg J, Gorgulu E, Lembeck P, Kraus N, Glitscher M, Uschner FE, Brol MJ, Gu W, Schierwagen R, Klein S, McCoy MS, Mucke MM, Wiedemann T, Reuken PA, Reissing J, Schneider F, Bohling N, Praktiknjo M, Tepasse PR, Fischer J, Zeuzem S, Welsch C, Ciesek S, Stallmach A, Trebicka J, Chang J, Bruns T, Hildt E, Peiffer KH. Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure. JHEP Rep. 2026 Apr;8(4):101627. doi: 10.1016/j.jhepr.2025.101627. Epub 2025 Oct 9.
Jonel Trebicka, MD, PhD
Goethe University Hospital Frankfurt
First Submitted
July 14, 2021
First Posted
July 23, 2021
Study Start
December 1, 2020
Actual (reported)Primary Completion
September 30, 2025
Estimated (date passed)To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
July 29, 2021
Record last verified: 2021-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: